Neptune Technologies & Bioressources Inc. Signs A World Wide Distribution Agreement With A Major Player
Monday, January 17 2005

Neptune Technologies & Bioressources Inc. Signs A World Wide Distribution Agreement With A Major Player

MONTREAL, Jan. 17, 2005 /CNW Telbec/ - Neptune Technologies & Bioressources Inc. is pleased to announce that its leading edge proprietary product, Neptune Krill Oil (NKO™) is now being distributed in 12 countries around the world, and will, during the current year, be launched in most of the 39 countries that Pharmanex, a division of NuSkin Enterprises, well known for its
"NuSkin™ brands", operates in.

"The deal with Pharmanex is strategically very important; it went efficiently through a very rigorous process and Neptune will definitely benefit from it. Pharmanex is one of the largest MLM Corporations and is now aggressively penetrating new countries with NKO™ said Tina Sampalis, M.D., Ph.D. Vice President, Research / Business & Development, at Neptune
Technologies & Bioressources Inc. "Moreover, being 1 of only 3 authorized MLM Companies to operate in China; we are looking forward for Pharmanex to bring NKO™ to China, as well. This is very exciting and promising for Neptune,"added Dr. Sampalis.

Neptune Technologies & Bioressources Inc. develops and exploits marine biomasses with its patented extraction process (Neptune OceanExtract™ utilizing marine biomasses, such as krill, and due to its technologies, Neptune Technologies & Bioressources Inc., is strategically well positioned in the $182 billion global nutrition market (Nutrition Business Journal, Oct/Nov 2004) based on the health and wellness concepts, markets in which natural biomass extraction is now playing an important role in developing nutrigenomics, the next wave in nutritional research.

Neptune Technologies & Bioressources Inc. is listed on the following Stock Exchange Market TSX-V Venture Exchange under the ticker symbol NTB.V, Berlin Exchange under the ticker symbol NTB.BE and the U.S Pink Sheets Exchange under the ticker symbol NPTZF.PK.

Neither NASDAQ nor TSX venture exchange accepts responsibility for the adequacy or accuracy of this press release.
Neptune Technologies and Acasti Pharma Contact:
Neptune Technologies & Bioressources Inc.
Acasti Pharma Inc.
Toni Rinow, Ph.D., MBA
Corporate Development & Investor Relations
(450) 687-2262
This e-mail address is being protected from spambots, you need JavaScript enabled to view it
# # #
Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission and the Canadian securities commissions.
 

We communicate

NTB (TSX) CAN$ 1.93 +0.03
NEPT (NASDAQ) US$ 1.898 +0.068
 

press releases

Investor Relations Contact NEPTUNE TECHNOLOGIES & BIORESSOURCES